Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6166 to 6180 of 8219 results

  1. COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Evidence summary: COVID-19 rapid summary
    Published
    5 June 2020

  2. COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)

    This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).

    Evidence summary: COVID-19 rapid summary
    Published
    29 June 2020

  3. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Evidence summary: COVID-19 rapid summary
    Published
    15 January 2021

  4. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Evidence summary: COVID-19 rapid summary
    Published
    20 January 2021

  5. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Evidence summary
    Published
    29 September 2015

  6. Postural hypotension in adults: midodrine (ESUOM5)

    This evidence summary has been updated and replaced by NICE evidence summary: new medicines 61.

    Evidence summary
    Published
    5 February 2013

  7. Pulmonary hypertension in neonates: sildenafil (ESUOM51)

    This evidence summary has been withdrawn following updated information in the summary of product characteristics on the off-label use of sildenafil (Revatio) in neonates with persistent pulmonary hypertension of the newborn.

    Evidence summary
    Published
    29 March 2016

  8. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Evidence summary
    Published
    10 March 2015

  9. Rapid tranquillisation in mental health settings: promethazine hydrochloride (ESUOM28)

    This evidence summary has been updated and replaced by NICE guideline NG10.

    Evidence summary
    Published
    11 March 2014

  10. Transient ischaemic attack: clopidogrel (ESUOM23)

    This evidence summary has been withdrawn and NICE accredited guidance is available from the Royal College of Physicians.

    Evidence summary
    Published
    13 December 2013

  11. Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Evidence summary
    Published
    6 January 2014

  12. Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)

    This evidence summary has been withdrawn because the product has been discontinued in the UK.

    Evidence summary
    Published
    20 February 2014

  13. Chronic pain: oral ketamine (ESUOM27)

    This evidence summary has been updated and replaced by NICE guideline NG193.

    Evidence summary
    Published
    25 February 2014

  14. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 22.

    Highly specialised technologies guidance
    Published
    20 July 2016

  15. Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)

    This guidance has been updated and replaced by NICE’s highly specialised technologies guidance on elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19).

    Highly specialised technologies guidance
    Published
    16 December 2015